Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 10, 2022 11:49am
307 Views
Post# 35088670

RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

why can't Oncy break through $2 on the NAS

ask your shorting friends.
not, even a week ago , they were touting under $1 , blah blah blah.
even some half Witt still on the other board yammering about ATM etc etc.
A few of my friends who bought last few weeks are quite happy with their 38% increase.
If they sell or not? Certainly not my concern.
The long game, will continue to play out.
the SP will go up & will go down.
However & this is what some are missing....
The comercial value of Pela & eventual value of Onc, has zero relevance to its trading SP.
should Roche see a 5x increase of tecentriq sales as a result of adding Pela...that determines the value of Pela & ONC.
Those shorting, today & no doubt there are, will get caught in a squeeze of a lifetime.
Onc is very thinly traded & subject to large % swings , both up & down.
The abstract further details will be realeased tomorrow @ a presentation in Boston.
The follow up on Monday. Will have a very wide audience.
could Onc be worth $3-$8billion on a take out?
That I do not know. I do know, the recent results scream for a phase 3 partner.
That deal will have $$$ attached to it , & will move tye SP, accordingly.
even a bargain basement price of $1billion, is $15ps.
so, relax, wait for the games to play out.
I'm not buying anymore, because I already did 2weeks ago.
certianky not selling.
presently the upside is unimaginable.
the downside?
not worth a short sale.
but if so inclined , please do.
I love watching a short squeeze.
Dont believe me, check out Dec 2019.
went from under $1 ( CDN) to a brief peak , over $6 ....in about 3 weeks.
short away!


 

<< Previous
Bullboard Posts
Next >>